Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Previous studies have shown that fast homoarginine-sensitive alkaline phosphatase (FHAP) is roughly equivalent to CEA (Roche) as a marker in colon cancer. The present study compares FHAP with CEA-EIA (Abbott) as a marker in cancer of the colon, breast, lung, ovary, uterus, skin, and lymph nodes. Comparison is made with regard to sensitivity, specificity, predictive value of a positive test, and diagnostic efficiency. It was determined that FHAP and CEA-EIA were comparable as markers for cancers of the colon, breast, and lung. FHAP was more sensitive and specific and had a higher predictive value and diagnostic efficiency for cancers of the ovary, uterus, skin, and lymph nodes.
 ...
PMID:A comparison of the predictive value and diagnostic efficiency of FHAP and CEA as cancer markers. 243 42

In 98 patients affected by colorectal cancer (43 patients with colon cancer, 55 patients with rectosigmoid cancer) the specificity of some tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) has been tested in evidencing the coexistence of liver metastases and the site of the primary tumor, i.e. the rectosigmoid region (rectum + 15 cm of the adjacent sigmoid colon) vs the rest of the colon. Liver metastases, present in 19 patients with colon cancer and in 24 with recto-sigmoid cancer, were previously ascertained by various instrumental investigations. Unlike previous studies which indicated CEA or alpha-FP as the most reliable markers to suggest the coexistence of liver metastases in such patients, the reported results allow the following sequence, in decreasing order of sensitivity, to be proposed: gamma-GT; FpA; CEA and GICA to a similar degree; TPA, which increases only when liver metastases from colon cancer are present; lastly, alpha-FP, which rises only in very few cases of massive hepatic involvement.
 ...
PMID:Specificity of tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) for the diagnosis of hepatic metastases from large bowel cancers. 247 62

Thirteen patients with a diagnosis of primary colorectal tumour and 68 patients previously operated for colon cancer underwent an immunoscintigraphy carried out with monoclonal antibodies anti-CEA F(ab')2, labelled with 131I or 111In. These studies led to the detection of all primary tumours and of most of their associated lesions (7/8). In this group 15 neoplastic deposits previously undetected were demonstrated, allowing an improvement in the patient staging before the operation. In the group of the 68 operated patients, immunoscintigraphy succeeded in imaging 96 out of 121 known lesions: the best outcomes were obtained for abdominal and pelvic recurrences as well as for lymph nodes lesions. The lowest levels of sensitivity were observed for liver metastases. An enhancement of the immunoscintigraphy sensitivity was obtained when the radiopharmaceutical was injected intraperitoneally. In 50 patients, this alternative administration route was successful in detecting 91/107 cancer deposits and, in particular, liver metastases were found out in 36/42 cases.
 ...
PMID:Immunoscintigraphy of primary and metastatic colorectal cancers with radiolabelled monoclonal antibodies anti-CEA. 248 18

The paper is concerned with comparative analysis of the results of the determination of activity of galactosyl transferase, CEA and antigen CA-125 in the blood serum of 44 healthy persons, 70 cancer patients and 12 patients with benign diseases. It was shown that a radiometric test for galactosyl transferase in its diagnostic sensitivity was not inferior to CEA in stomach and ovarian tumors and exceeded the test for antigen CA-125 in ovarian cancer. In colon cancer the diagnostic accuracy of the tests for the activity of galactosyl transferase and CEA turned out to be identical. The most reliable diagnostic test in acute lymphoblastic leukemia in children was the test for galactosyl transferase activity.
 ...
PMID:[Blood serum galactosyltransferase in oncologic diseases]. 249 14

Anti-CEA monoclonal antibody was labeled with 111In using DTPA cyclic anhydride. The radiochemical purity of the product was more than 99% and specific binding was 38%. Imaging and biodistribution of this radiopharmaceutical in nude mice bearing human colon cancer xenografts were investigated. The results showed that a clear image of tumor was obtained by gamma camera between 24 to 120 hrs, best in 72 hrs, after injection. A high uptake of 111In-labeled monoclonal antibodies in tumor tissue was also observed, although the radioactivity in liver was considerable.
 ...
PMID:[Imaging and biodistribution of 111In-labeled anti-carcinoembryonic antigen monoclonal antibodies in nude mice bearing human colon cancer xenografts]. 262 5

The nature of the antigen recognized by the murine monoclonal antibody A7 (Mab A7) against human colorectal carcinoma was investigated using immunochemical and biochemical techniques. Binding activity of 125I-labeled Mab A7 was examined using various human cancer cell lines. Mab A7 gave the highly specific binding to colon cancer cell lines, SW1116 and WiDr, and gave only a very weak or no reactivity to gastric cancer cell lines, pancreas cell lines or lung cancer cell lines. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting of the extractable antigen from SW1116 showed a single band at approximately 45,000 dalton formed by 125I-labeled Mab A7. Treatment of SW1116 with sodium periodate, pronase and ficin resulted in the loss of antigenic activity. These data strongly suggest that the antigen recognized by Mab A7 is composed of glycoprotein. Competitive binding analysis to the surface of the colon cancer cell line using polyclonal anti-CEA and Mab A7 as well as immunoblotting analysis using monoclonal anti-CEA and Mab A7 suggested that the antigen recognized by Mab A7 was different from CEA. Moreover, this antigen was also found in surgical specimens of colorectal cancer patients and its molecular property was identical to the antigen extracted from SW1116.
 ...
PMID:Immunochemical characterization of the antigen recognized by the murine monoclonal antibody A7 against human colorectal cancer. 271 85

The presence of human chorionic gonadotropin in large bowel cancers was studied immunohistochemically using an immunoperoxidase technique. HCG-positive tumour cells were present in 42 of 194 adenocarcinomas examined (22.0% of colon cancer and 21.2% of rectal cancers). On histological grading, the hCG-positive rate tended to rise as the degree of differentiation decreased. HCG was detected more frequently in cancers invading the total bowel wall (27%) than in those invading the partial wall (17.1%). Lymph node, liver or peritoneal metastases were present more frequently in hCG-positive tumours than in hCG-negative tumours. Furthermore, there was an intimate correlation between the presence of hCG-positive tumour cells and CEA doubling times in nine cases with untreated liver metastasis. The survival rate for patients with tissue hCG-positive cells was lower than for those with hCG-negative tumours. Thus, the presence of tissue hCG in colorectal cancers may be a biological marker of prognostic significance.
 ...
PMID:Human chorionic gonadotropin in colorectal cancer and its relationship to prognosis. 278 46

The follow-up of colon cancer patients by monitoring serum carcinoembryonic antigen has advantages (better survival after early detection of recurrence by CEA rise) as well as disadvantages (false-positive rise of CEA, and early detection of incurable recurrences in asymptomatic patients). The effects of CEA follow-up on quality-adjusted life expectancy (QUALE) of patients with curatively resected colon carcinoma have been simulated by a Markov analysis using literature data. The value of CEA seems insignificant and varies, depending on the literature data used, from a mean increase of QUALE by 6 days (+0.4%) to a mean decrease by 2 days (-0.07%). This value depends on patient-related variables; the negative effects of CEA especially predominate in older patients with favourable Dukes' stages of primary tumour.
 ...
PMID:[Carcinoembryonal antigen and the follow up of patients after resection of colon carcinoma with curative intent: a Markov process in decision analysis]. 281 76

We report here on a patient with recurrent sigmoid colon carcinoma. Postmortem examination revealed a fist-sized tumor in the retroperitoneum, invasive to the left ureter obstructing its lumen causing hydronephrosis of the ipsilateral kidney. Histological examination of the kidney showed multiple foci of adenocarcinoma cells on the pelvic surface. Invasion into the underlying tissue was not observed, and there was no tumor in the submucosal tissue of the pelvis or in the parenchyma of the left kidney. Cancer cells on the renal pelvic mucosa showed strong immunoreactivities for CEA and CA 19-9. These findings suggest that the tumor foci in the pelvis are formed by the intraluminal implantation of colon cancer cells detached from the ureteric metastasis. Our case presents the possibility of the implantation of carcinoma cells in the human urinary tract.
 ...
PMID:Implantation of colon cancer cells onto renal pelvic mucosa. A case report. 292 Jan 5

Administration of a large dose (0.2 mg) of unlabeled specific anticarcinoembryonic antigen (anti-CEA) monoclonal antibody (MAB) to nude mice bearing LS174T human colon cancer xenografts significantly decreased normal liver uptake of 111In-labeled anti-CEA MAB (Indacea). Mice bearing tumors of approximately 1 g showed liver accumulation of indium-111 at 48 h following injection of 2 micrograms/10 microCi Indacea of 33.8 +/- 1.5% injected dose per gram (%ID/g) (N = 25). Treatment with 0.2 mg unlabeled anti-CEA MAB reduced this to 8.9 +/- 0.5% ID/g (N = 22; P less than 0.001). The dose of pretreatment was found to be critical. Increasing the amount of unlabeled MAB to 2.0 mg did not significantly improve the liver level of indium-111, but did compromise the tumor uptake of Indacea (15.9 +/- 1.3 versus 12.4 +/- 0.4% ID/g; P less than 0.05). Lowering the dose of pretreatment 10-fold resulted in increased (P less than 0.001) liver uptake of the label (26.5 +/- 2.8% ID/g). The unlabeled anti-CEA MAB treatment given as a single dose or fractionated over several days gave the same results. The decrease in liver uptake was the same for i.v. administration of the unlabeled MAB given 1 week prior to Indacea injection or mixed together with Indacea. With i.p. administration, simultaneous injection of the unlabeled MAB with Indacea was not as effective as pretreatment (20 min to 7 days) in decreasing the liver uptake of 111In (P less than 0.05). Epitope specificity and affinity were shown to be important considerations in the choice of MAB combinations used for pretreatment and imaging. Pretreatment with nonspecific MAB was ineffective in decreasing liver uptake of Indacea.
 ...
PMID:Effect of specific antibody pretreatment on liver uptake of 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts. 292 9


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>